New River Pharmaceuticals Inc

New River Pharmaceuticals — Technical Presentation (June 2006)

19 slides from New River Pharmaceuticals's technical presentation, Jun 19, 2006

  1. Slide 1: Pharmacokinetics of Oral Lisdexamfetamine Dimesylate Versus d-Amphetamine Sulfate

    Slide 1: Pharmacokinetics of Oral Lisdexamfetamine Dimesylate Versus d-Amphetamine Sulfate

    Pharmacokinetics of Oral Lisdexamfetamine Dimesylate (LDX; NRP 104) Versus d- Amphetamine Sulfate in Healthy Adults With a History of Stimulant Abuse (NRP104.A01) Donald Jasinski The Johns Hopkins University, Baltimore, MD Suma Krishnan New River Pharmaceuticals, Blacksburg, VA

  2. Slide 2: LDX (lisdexamfetamine dimesylate): d-amphetamine bonded to l-lysine

    Slide 2: LDX (lisdexamfetamine dimesylate): d-amphetamine bonded to l-lysine

    d-amphetamine covalently bonded to l-lysine Pharmacologically inactive until cleaved via rate-limiting hydrolysis Resistant to manipulation and difficult to extract d-amphetamine LDX (lisdexamfetamine dimesylate)

  3. Slide 3: Protocol Objectives

    Slide 3: Protocol Objectives

    To determine safety and tolerability of single oral dose of lisdexamfetamine dimesylate (LDX) in 12 healthy adults with histories of stimulant abuse To compare PK profile of LDX with d- amphetamine and placebo To determine safe and tolerable dosing for further study Protocol Objectives

  4. Slide 4: Design and Methodology

    Slide 4: Design and Methodology

    Partially randomized, single-blind, dose-escalation study; Subjects on inpatient unit at least 14 days Subjects met DSM-IV criteria for stimulant abuse; Screening for medical and psychiatric histories; naloxone challenge included Design and Methodology

  5. Slide 5: Design and Methodology: Dosing Cohorts

    Slide 5: Design and Methodology: Dosing Cohorts

    Placebo LDX 30 mg, 50 mg, 70 mg, 100 mg d- amphetamine sulfate 40 mg Cohort = 4 Placebo LDX 50 mg, 70 mg, 100 mg, 130 mg d- amphetamine sulfate 40 mg Cohort = 4 Placebo LDX 70 mg, 100 mg, 130 mg, 150 mg d- amphetamine sulfate 40 mg Cohort = 4 Design and Methodology Minimum dosing interval: 48 h d-am

  6. Slide 6: Patient Disposition

    Slide 6: Patient Disposition

    subjects were given at least 1 dose subjects completed the study subject was discontinued due to “reactive hypertension” after 2nd dose of d-amphetamine sulfate 40 mg Patient Disposition

  7. Slide 7: d-amphetamine sulfate and LDX equal molar amounts of d-amphetamine base

    Slide 7: d-amphetamine sulfate and LDX equal molar amounts of d-amphetamine base

    d-amphetamine sulfate 40 mg and lisdexamfetamine dimesylate contain equal molar amounts of d-amphetamine base

  8. Slide 8: Cohort plasma concentration charts

    Slide 8: Cohort plasma concentration charts

    Cohort Cohort Cohort and Cohort 2

  9. Slide 9: Plasma concentration over hours by dose

    Slide 9: Plasma concentration over hours by dose

    Hours - Placebo - 7OmgLDX -« 100 mgLDX -=- 130 mg LDX | 150mgLDX -* 40 mg d-amp

  10. Slide 10: Pharmacokinetics by Cohort

    Slide 10: Pharmacokinetics by Cohort

    LDX 100 mg d-amphetamine sulfate 40 mg Cohort T max d -amp (hours) C max d -amp (ng/mL) T max d -amp (hours) C max d -amp (ng/mL) 3.78 81.9 2.74 109.0 4.25 85.0 2.75 87.5 3.98 104.0 1.88 111.0 Pharmacokinetics by Cohort

  11. Slide 11: Results

    Slide 11: Results

    Results Dose appeared to attenuate between 130 to 150 mg of lisdexamfetamine Doses to 150 mg lisdexamfetamine safe and tolerable for further study Prolonged absorption phase as result of rate limiting hydrolysis

  12. Slide 12: Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study (NRP104.A03)

    Slide 12: Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study (NRP104.A03)

    A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP 104 in Healthy Adult Volunteers with Histories of Stimulant Abuse (NRP104.A03)

  13. Slide 13: Design and Methods

    Slide 13: Design and Methods

    Design and Methods male and 6 female stimulant abusers Six 6X6 balanced Latin squares for crossover design Primary variable is maximum score on VAS scale to item “ How much do you like the drug effects you are feeling now?”

  14. Slide 14: Drug and doses given orally

    Slide 14: Drug and doses given orally

    Drug and doses given orally Placebo mg d-amphetamine (Schedule II) mg diethylpropion (Schedule IV) Pro-drug Subjective and behavioral effects comparable to d-amphetamine 40 mg lisdexamfetamine mg (base = d-amp 20 mg) 100mg (base = d-amp 40 mg) mg (base = d-amp 60 mg)

  15. Slide 15: Primary Endpoint: Peak Liking Score

    Slide 15: Primary Endpoint: Peak Liking Score

    Dependent Variable: Do you like the drug effect you are feeling now? Drug (I) Drug (J) Mean Difference (I – J) Std. Error Significance 95% Conf. Interval ( Lower Bound) d-amphetamine 40mg Placebo 4.53* 1.148 < 0.001 1.94 diethylpropion 200mg Placebo 4.03* 1.148 0.001 1.44 LDX 100mg Placebo 2.14 1.14

  16. Slide 16: Primary Endpoint: Peak Liking Score (LDX doses)

    Slide 16: Primary Endpoint: Peak Liking Score (LDX doses)

    Dependent Variable: Do you like the drug effect you are feeling now? Drug (I) Drug (J) Mean Difference (I – J) Std. Error Significance 95% Conf. Interval ( Lower Bound) LDX 50mg Placebo 1.97 1.148 0.148 -0.61 LDX 100mg Placebo 2.14 1.148 0.113 -0.45 LDX 150mg Placebo 6.06* 1.148 0.001 3.47 Based on

  17. Slide 17: Peak Liking Scores

    Slide 17: Peak Liking Scores

    d-amphetamine and diethylpropion 1.5 to 2 hours NRP104 to 4 hours Peak Liking Scores

  18. Slide 18: Top Line Results

    Slide 18: Top Line Results

    Top Line Results LDX attenuates onset and intensity of liking effects Liking effects of LDX 50 and 100mg not significantly different than placebo Liking effects of LDX 150 mg greater than placebo but similar to d-amphetamine and diethylpropion however mean peak effect delayed

  19. Slide 19: Top Line Results

    Slide 19: Top Line Results

    Top Line Results Rate limited hydrolysis of LDX in humans Pro-drug attenuates onset and intensity of amphetamine like effects Attenuated Liking Scale scores Less reinforcing than equivalent d-amphetamine or diethylpropion Contribute to lesser abuse potential

Source: SEC EDGAR · 8-K filed Jun 19, 2006

More decks from New River Pharmaceuticals Inc